Buprenorphine Hydrochloride

證據等級: L5

預測適應症: 0 個

Buprenorphine Hydrochloride: Drug Repurposing Evaluation — Insufficient Data for Full Assessment

One-Sentence Summary

Buprenorphine Hydrochloride is a well-known partial opioid agonist used clinically for opioid use disorder and pain management. However, the current Evidence Pack contains no TxGNN predicted indications, and critical drug-level data — including original approved indications and mechanism of action — are absent from the structured data fields. A complete repurposing evaluation cannot be conducted at this stage; this report summarises what is available and outlines what is needed to proceed.

Quick Overview

Item	Content
Original Indication	Not populated in current Evidence Pack
Predicted New Indication	Not available — TxGNN predictions absent
TxGNN Prediction Score	Not available
Evidence Level	Not evaluable
Taiwan Market Status	✗ Not marketed
Number of Authorizations	0
Recommended Decision	Hold

Why the Data Gap Matters

Without a predicted indication from TxGNN, this report cannot fulfil its core purpose: explaining why a drug's mechanism might extend to a new disease area.

The query log does show that both a DrugBank lookup and a TFDA package insert query returned 1 result each, meaning raw data likely exists upstream. However, neither the mechanism of action nor the approved indication text was propagated into the Evidence Pack fields. Until those fields are populated, mechanistic reasoning is not possible.

Currently, detailed mechanism of action data is not available in the structured Evidence Pack. Based on general pharmaceutical knowledge, Buprenorphine Hydrochloride is a partial agonist at μ-opioid receptors and an antagonist at κ-opioid receptors, approved in many jurisdictions for opioid use disorder (OUD) and chronic pain. Its repurposing potential — for example in treatment-resistant depression or neonatal abstinence syndrome management — is an active area of clinical research, but no formal TxGNN prediction is recorded here to anchor this evaluation.

Taiwan Market Information

No authorizations were found in the Taiwan TFDA database. Buprenorphine Hydrochloride is not currently marketed in Taiwan under any registered product.

Safety Considerations

Please refer to the package insert for safety information.

Note: The TFDA package insert query returned 1 result, but the warnings and contraindications fields were not populated in this Evidence Pack. This is a pipeline data extraction issue rather than a genuine absence of safety information for this drug class.

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack is critically incomplete on all evaluable dimensions — no TxGNN predictions, no original indication, no MOA, and no safety data. Issuing a Go or Proceed-with-Guardrails recommendation without these inputs would not be clinically responsible.

To proceed, the following is needed:

TxGNN predictions: Re-run the model for Buprenorphine Hydrochloride and confirm at least one predicted indication with score and evidence links
Original indication: Extract from the TFDA package insert result already retrieved (query ID 4, status: success) — the text needs to be parsed into drug.original_indications
Mechanism of action: Extract from the DrugBank result already retrieved (query ID 3, status: success) — populate drug.original_moa
Safety data: Parse key warnings and contraindications from the same package insert source — populate safety.key_warnings and safety.contraindications
DDI data: The DDI query returned not_found; consider querying a secondary source (e.g. DrugBank interaction API or FDA label) given that buprenorphine has clinically significant interactions with CNS depressants and CYP3A4 inhibitors
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.